Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy

Ruben Rhoades; Ron Leong; Jason Kopenitz; Brandi Thoma; Lydia McDermott; Joseph Dovidio; Shannon Barletti; Jerald Z Gong; Howard T Massey; Steven E McKenzie; J Eduardo Rame; Nawar Al-Rawas

doi:10.1016/j.thromres.2021.04.008

Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy

Thromb Res. 2021 Jul:203:1-4. doi: 10.1016/j.thromres.2021.04.008. Epub 2021 Apr 19.

Authors

Affiliations

¹ Division of Hematology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, United States of America. Electronic address: ruben.rhoades@jefferson.edu.
² Critical Care Division, Department of Anesthesia, Thomas Jefferson University, Philadelphia, PA, United States of America.
³ Deparment of Pharmacy, Thomas Jefferson University, Philadelphia, PA, United States of America.
⁴ Department of Pathology, Anatomy, & Cell Biology, Thomas Jefferson University, Philadelphia, PA, United States of America.
⁵ Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University, Philadelphia, PA, United States of America.
⁶ Division of Hematology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, United States of America.
⁷ Division of Cardiology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, United States of America.

No abstract available

Keywords: Activated partial thromboplastin time (aPTT); Acute respiratory distress syndrome (ARDS); Anti-Xa; COVID-19; Coagulopathy; Extracorporeal membrane oxygenation (ECMO); Heparin.

Publication types

Letter

MeSH terms

Anticoagulants / adverse effects
COVID-19*
Extracorporeal Membrane Oxygenation*
Heparin / adverse effects
Humans
Partial Thromboplastin Time
Retrospective Studies
SARS-CoV-2

Substances

Anticoagulants
Heparin